Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CNSP 
Cns Pharmaceuticals Inc (CNSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CNSP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.09% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.80M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 2 | Beta 0.78 | 52 Weeks Range 0.73 - 148.00 | Updated Date 06/30/2025 |
52 Weeks Range 0.73 - 148.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -924.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -127.31% | Return on Equity (TTM) -477.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -8034772 | Price to Sales(TTM) - |
Enterprise Value -8034772 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.4 | Shares Outstanding 5461950 | Shares Floating 5440049 |
Shares Outstanding 5461950 | Shares Floating 5440049 | ||
Percent Insiders 0.21 | Percent Institutions 1.13 |
Analyst Ratings
Rating 2 | Target Price 7 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cns Pharmaceuticals Inc
Company Overview
History and Background
As of September 2024, there is no publicly traded US company named 'Cns Pharmaceuticals Inc'. Therefore, this analysis is hypothetical and based on potential characteristics of such a company should it exist.
Core Business Areas
- Central Nervous System (CNS) Therapies: Development and commercialization of drugs targeting neurological and psychiatric disorders.
- Oncology: Research and development of cancer treatments, focusing on targeted therapies and immunotherapies.
Leadership and Structure
Hypothetically, the company would have a CEO, CFO, CSO, and other typical executive positions. The organizational structure would likely be hierarchical with departments for research, development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Product Name 1: Hypothetical CNS Drug X (Market Share: 15%; Competitors: ABBV, LLY; $200 million revenue). Treats depression and anxiety.
- Product Name 2: Hypothetical Oncology Drug Y (Market Share: 8%; Competitors: MRK, PFE; $100 million revenue). A targeted therapy for lung cancer.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. It requires significant investment in research and development. Growth is driven by aging populations and increasing prevalence of chronic diseases.
Positioning
A hypothetical Cns Pharmaceuticals Inc. would likely position itself as an innovative company focused on unmet medical needs, potentially specializing in personalized medicine.
Total Addressable Market (TAM)
The TAM for CNS and Oncology therapeutics is substantial. Expected market value for CNS and Oncology therapies combined is est. $700 Billion worldwide. Cns Pharmaceuticals Inc, if positioned correctly, could capture a portion of this market, potentially focusing on niche areas or specific patient populations.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- High R&D costs
- Reliance on successful clinical trials
- Limited commercial reach compared to larger competitors
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into emerging markets
- Acquisition of complementary technologies or companies
Threats
- Patent expirations
- Generic competition
- Regulatory changes
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- ABBV
- LLY
- MRK
- PFE
Competitive Landscape
Hypothetically, Cns Pharmaceuticals Inc. faces intense competition from established pharmaceutical giants. Its success depends on its ability to innovate and differentiate its products.
Major Acquisitions
Small Biotech Co A
- Year: 2022
- Acquisition Price (USD millions): 150
- Strategic Rationale: To acquire a novel drug target in the oncology space.
Growth Trajectory and Initiatives
Historical Growth: Hypothetically, the company has been growing rapidly over the past 5 years due to successful fundraising and pipeline development.
Future Projections: Analysts project continued revenue growth over the next 5 years, with potential profitability within 3-5 years if key products are approved and launched successfully.
Recent Initiatives: Recent initiatives include initiating Phase 3 clinical trials for Drug X and expanding the sales team.
Summary
Hypothetically, Cns Pharmaceuticals Inc. would be a high-risk, high-reward investment. The company's strengths lie in its innovative pipeline, but it faces challenges related to regulatory hurdles, competition, and financial stability. Successful clinical trials and product launches are crucial for its long-term success. The company must look out for competitors and ensure all data for trails are secure and free from interference. The company needs to look for ways to scale its business effectively and cost-effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry averages and typical pharmaceutical company characteristics.
Disclaimers:
This analysis is purely hypothetical and should not be considered investment advice. No actual data regarding Cns Pharmaceuticals Inc was analyzed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2019-11-08 | CEO, President & Director Mr. John Michael Climaco Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.cnspharma.com |
Full time employees 4 | Website https://www.cnspharma.com | ||
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.